Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) (NCT06462365)
Phase I, First in Human, Open Label Study to Evaluate Safety and Tolerability of TRX103 Cells in Subjects With Hematological Malignancies Undergoing HLA-mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT). It is anticipated that up to 36 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time post HSCT.
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (5 Sites)
- City of Hope — Duarte, California
- Dana-Farber Cancer Institute — Boston, Massachusetts
- University of Minnesota — Minneapolis, Minnesota
- Memorial Sloan Kettering Cancer Center — New York, New York
- Fred Hutchinson Cancer Center — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (858) 283-7879
Email: Tr1xClinicalTrials@Tr1x.bio
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hematologic Malignancy
- A Positive Psychology Based Intervention (PATH-C) for Caregivers of HSCT Survivors — Boston, Massachusetts
- Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation — New York, New York
- Novel 3D Hematological Malignancy Organoid to Study Disease Biology and Chemosensitivity — Winston-Salem, North Carolina
- Patient Fitness and Body Composition During Hematopoietic Stem Cell Transplantation — Seattle, Washington
- Critical Care Outcomes of Hematologic Oncology Patients — Calgary, Alberta
- Expressive Writing Program Among Young Adults With Blood Cancer — Washington D.C., District of Columbia
Explore by condition: All Hematologic Malignancy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.